Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road South West
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
18
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,536.26 | 33.48 | 0.45% |
| DAX 40 | 22,242.45 | 177.94 | 0.81% |
| Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
| FTSE 100 | 8,415.25 | 7.81 | 0.09% |
| HKSE | 21,980.74 | 70.98 | 0.32% |
| NASDAQ | 17,382.94 | 216.90 | 1.26% |
| Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,525.21 | 40.44 | 0.74% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,295.06 | 2.23 | -0.07% |